Molecular genetics has revolutionized the way one should consider a patient with muscular dystrophy. The purpose of this Perspectives article is to set the parameters by which physicians may judge their neuromuscular patients in the context of recent advances in the understanding of both genetic and biochemical aspects of muscular dystrophy. We will first review some of the progress that has occurred over the past 5 years. This will illustrate how advances at the basic science level have led directly to powerful new diagnostic tests and, hence, to a new "molecular definition" of Duchenne and Becker muscular dystrophies (DMD and BMD).' After discussing the strengths and weaknesses and appropriate use of these tests, we will end with specific examples of their use in a clinical setting. We hope this review will aid in the rapid transition of these tests from the research laboratory to routine clinical use.
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Background
Duchenne muscular dystrophy is a severe, progressive, muscle-wasting disorder that leads to loss of ambulation by 1 1-12 yr of age and, eventually, death by the third decade, often due to pulmonary insufficiency (1) (2) (3) . BMD is a milder form in which a similar clinical course is followed but at a much slower and more variable rate (3) . These patients generally become wheelchair-bound sometime after 15 yr and some may remain ambulatory into their 60s. The incidence cf DMD/BMD is extremely high for a genetic disease (1 in 3,500 male births with DMD being about 10 times more common than BMD), and it has been estimated that up to one-third of cases represent new mutations (2) . The unequal sex distribution provided the first clue to the genetic location of these diseases on the human X chromosome. Careful cytogenetic analysis of several unusual patients led to the finding that abnormalities (deletions and translocations) of the middle of the short arm of the X (Xp2 1) could result in muscular dystrophy (4, 5) . Once a tentative location was known, linkage studies were undertaken using randomly cloned DNA probes from this region of the chromosome (6). These reports not only confirmed the local- 1 . Abbreviations used in this paper: BMD and DMD, Becker and Duchenne muscular dystrophies; CPK, creatine phosphokinase; PCR, polymerase chain reaction; RFLP, restriction fragment length polymorphism.
ization of the DMD gene to Xp2 1, but they also provided the first evidence that DMD and BMD are actually allelic disorders; i.e., they are both caused by different mutations to the same gene (7) .
After an intensive effort by a number of laboratories, parts of the actual gene itself were first isolated by two groups, within 6 months of each other, in late 1986 and early 1987 (8, 9) . When these early genomic DNA probes were used to examine DNA from patients with DMD and BMD, it was found that up to 5% had gene deletions (10) (11) (12) . However, linkage analysis in families without detectable deletions suggested that mutations causing DMD could occur at great distances on either side of the cloned probes (13, 14) . This apparent paradox was resolved when the entire cDNA was cloned (15) . The 14-kilobase (kb) transcript was found to be encoded for by more than 70 exons spread over nearly 2,500 kb of genomic DNA (15) (16) (17) . This enormous size presumably explains the high mutation rate since the gene presents such a large target (sizes for "average genes" have a range of 3-300 kb).
Pieces of the cDNA could now be used as probes to specifically examine all of the exons by Southern blot analysis, revealing that about 65% of DMD and BMD patients had deletions or duplications of one or more exons ofthis gene (15, 18, 19) . The cDNA was also used to produce fusion proteins ofthe DMD gene product in bacteria (20) . Antisera raised against these products recognized a large 400-kD, muscle-specific protein that was named "dystrophin" (20) . Sequence analysis of the cDNA had suggested that dystrophin was a component of the membrane cytoskeleton inasmuch as it was related to two other cytoskeletal components, a-actinin and spectrin (21) (22) (23) . This prediction was supported by the immunologic localization ofdystrophin to the inner face ofthe myofiber cell membrane (24) (25) (26) (27) . When antisera were used to examine dystrophin in muscle biopsies from patients with various neuromuscular diseases, it was found that patients with DMD invariably had absence of detectable dystrophin, whereas those with BMD had dystrophin of altered size and/or quantity (26, 28, 29 (28) . After transferring the proteins to a nitrocellulose membrane, the remaining gel is stained and examined for residual myosin. This provides an internal control for degradation and equal loading of lanes (28) . It also controls for tissue type since myosin, like dystrophin, is a muscle-specific protein. Dystrophin is visualized by successively incubating the nitrocellulose membrane in sheep anti-dystrophin and immunoperoxidase-conjugated rabbit anti-sheep IgG, followed by developing for peroxidase (28) . By comparison to adjacent control lanes either visually or by densitometry, the quality (size) and quantity of dystrophin are assessed ( Fig. 1 A) . All told, this process takes 3 d from start to finish.
In general, the complete absence ofdystrophin is predictive of DMD (> 99% accuracy), whereas the presence of larger-or smaller-sized, and/or the reduced abundance of, dystrophin establishes a diagnosis of BMD (> 95% accuracy) (28, 29) . Patients with < 20% normal levels of dystrophin often exhibit an intermediate phenotype, becoming wheelchair bound be-A) 1 2 3 4 5 6 tween the ages of 13 and 20 yr (so-called "outliers") (31) . Although the test is still in its infancy, our laboratory's experience with over 400 biopsies has revealed only two "DMD" cases with normal-appearing dystrophin. One of these cases was sporadic but the other had a history of consanguinity, suggesting that these patients represented a rare autosomal recessive variant ofmuscular dystrophy (32) . Two other apparent exceptions were two patients clinically diagnosed as BMD but who had no detectable dystrophin. Subsequent DNA analysis showed that both had large deletions encompassing the region of dystrophin used to raise the antibodies. In fact, when these patients were later retested with antisera raised against a different part of the molecule, dystrophin was detected, thus confirming the clinical diagnosis of BMD at the molecular level and underscoring the need to use multiple antisera for some patients (33) .
Although immunoblotting is clearly a sensitive diagnostic test for DMD and BMD in boys, it is not capable of detecting the small reductions ofdystrophin levels in most DMD carrier females. An alternate approach is to culture myoblasts from suspected carriers and perform dystrophin analysis on clonal populations of cells that had been induced to fuse into myotubes (34) . Since females randomly inactivate one X chromosome in each cell, roughly half ofcolonies from a DMD carrier are expected to express dystrophin while the other half are not. On the one hand, although this method is time-consuming and expensive, it may be the most sensitive approach to carrier detection for DMD and BMD. On the other hand, our limited experience with manifesting carriers suggests that dystrophin 
Immunohistochemistry
Indirect immunofluorescence on frozen sections of muscle provides a complementary approach to western blotting for dystrophin analysis. In normal individuals, dystrophin immunostaining is detected as a homogeneous ring around the periphery of all muscle fibers (24) (25) (26) . Muscle from DMD patients has no detectable staining, but in patients with BMD, the staining may range from almost normal to patchy and significantly lighter (35) . Although quite useful in males, the test is most useful for detecting female DMD carriers who often have patches of negative fibers among positive fibers owing to X chromosome inactivation (Fig. 1 B) (Fig. 2 A) An early observation was that dystrophin gene deletions were preferentially found within one of two hotspot regions at the 5' end and at 7-8 kb on the cDNA (15, 18) . As a result of this clustering, the majority of deletions can be detected by examining only a subset of exons. Multiplex PCR analysis takes advantage of this fact resulting in extremely rapid screening for deletions (Fig. 2 B) . Using two mixtures of primers that amplify nine exons each, over 98% of cDNA-detectable deletions can now be identified by PCR (43, Beggs,  A. H., and L. M. Kunkel, unpublished data). The primary advantages over Southern blotting are speed (1-2 d compared to 1-2 wk) and sensitivity (as little as 0.5 ml of blood), and current research is aimed at automating this procedure even more. However, until primers are designed for many more exons, PCR will not be able to predict the effects of deletions on the reading frame.
RFLP-based linkage analysis
Only 65% of patients have mutations detectable by Southern blot or PCR analysis. The remainder of confirmed cases are presumably due to point mutations, other types of alterations to noncoding sequences, or deletion/duplications of exons not detected by current assays. In these families, one must resort to linkage analysis employing Southern blotting and determination of RFLPs within and flanking the gene (6, 7) . With the advent of the rapid and direct approaches outlined above, this has become the most laborious and time-consuming procedure. In cases with a positive family history, DNA is obtained from the relevant family members. As many as seven or eight individuals may be necessary, and a common problem is the absence of key family members who have either died or are unavailable for analysis. DNA samples from each individual are cleaved with a series of restriction enzymes that define the particular alleles detected by a cloned DNA segment. To be "informative," a probe must recognize a restriction site that is polymorphic in the family being studied. By correlating the inheritance pattern of these RFLPs with the inheritance of the disease, one can identify a "haplotype" ofalleles that identifies the chromosome carrying a mutation. One caveat is that since the mutation itself is not identified, genetic recombination between the mutation and a RFLP-defined locus may abolish the association (13) . To identify these events, it is necessary to follow RFLPs flanking the gene as well. as markers within the gene itself. Thus, as many as 20 probe/allele combinations may need to be tested in each family member. This analysis leads to probabilistic estimates of the likelihood that a given individual has inherited the chromosome carrying a mutation.
As more sequence data become available, PCR-based assays are being developed thus allowing rapid allele determination for many ofthe more informative RFLPs (44) . A recent development is the finding that short tandem repeats (e.g., CACA... ) tend to be highly polymorphic in repeat number (45) . The resulting size variation is detectable as differences in the mobility of PCR products encompassing these regions. Recently, we and others have developed PCR assays to detect variation of one such repeat at the 3' end of the dystrophin gene (46, 47) . In the future, multiplex PCR assays for this and other similar polymorphisms will undoubtedly make linkage analysis much faster and simpler.
A protocolfor "molecular diagnosis" ofmuscular dystrophy Fig. 3 outlines the general protocol that we recommend when working up a patient with newly diagnosed muscle weakness. Of course, this entire discussion is predicated on the assumption that a complete neuromuscular workup has been performed, including CPK Currently, DNA studies are offered by many of the DNA diagnostic laboratories that are springing up at major medical centers. Until now, dystrophin testing has been available only through several research laboratories on an informal basis, however this is changing rapidly as more diagnostic laboratories begin to offer these services. Thus, it is our belief that, in future, all muscle biopsies should have at least one piece of tissue flash frozen in isopentane at -70'C to allow for eventual protein testing of dystrophin (or any other tests that may be developed).
The last few years have seen many exciting advances in our understanding ofthe underlying defects in DMD and BMD. It is extremely gratifying to see the rapidity with which this knowledge has been used to directly benefit patients and their families. We hope that these advances will soon lead to the development of rational and effective therapies for these devastating diseases.
Illustrative case histories Case 1. The patient is a 4-yr-old boy with a waddling gait and difficulty climbing stairs. He walked at 10 mo. The physical examination revealed him to have mild proximal muscle weakness including a positive Gower's sign. The laboratory findings were significant for a CPK level > 5,000 (normal < 200). Family history was negative for neuromuscular disease. The patient had two asymptomatic siblings. His 10-yrold brother had a CPK level within the normal range, and his 16-yr-old sister's CPK level was slightly elevated. His mother's CPK level was normal. The patient's muscle biopsy was consistent with muscular dystrophy and a clinical diagnosis of Duchenne muscular dystrophy was made.
Question: What can be done to confirm a diagnosis at this early stage, and are carrier detection and prenatal diagnosis possible for the patient's mother and sister? Answer To establish a diagnosis, a frozen piece ofthe preexisting muscle biopsy was sent for dystrophin testing. The absence of detectable dystrophin confirmed a diagnosis of DMD (e.g., as in Fig. I A,  lane 2) . PCR testing of the patient's DNA revealed a deletion within the dystrophin gene (e.g., Fig. 2 B, lane 4) . Subsequent Southern blot analysis on DNA from the patient (e.g., Fig. 2 A, lane 4) and his mother and sister confirmed the deletion and revealed that both women had one normal and one deleted copy of the dystrophin gene (females not shown). On the basis of these findings, both were counseled that they were indeed carriers and that upon future pregnancies each could be offered prenatal diagnosis.
Case 2. This patient is an 8-yr-old boy who presented with a recent history of toe walking and intermittent leg pain. He had previously normal motor development and was active in sports. The physical examination was remarkable for calf hypertrophy, difficulty with heel walking, and tightened Achilles Question: Can the diagnosis be definitively established? Answer: Dystrophin testing revealed that the patient's muscle contained dystrophin of -380 kD (normal 400 kD) and near-normal abundance (e.g., Fig. 1 A, lane 4) . PCR testing detected a deletion (e.g., Fig. 2 B, lane 1) Question: Is this patient a manifesting carrier for DMD, or does she suffer from some unrelated disorder? Answer: Immunofluorescence for dystrophin in cryostat sections from a muscle biopsy revealed patches of dystrophin-negative fibers indicative of the carrier state (e.g., Fig. 1 B) . Interestingly, immunofluorescence of the patient's identical twin's muscle was normal. The occurrence of one manifesting carrier in twin combinations has been reported previously and may involve unequal X-chromosome inactivation as a direct result of the twinning process (48) . Because PCR deletion analysis of DNA from the nephew failed to detect a deletion, RFLP-based linkage studies were performed so prenatal diagnosis could be offered in future pregnancies.
Case 4. This patient is a 6-yr-old boy with a history of severe limb girdle weakness of longstanding duration. His physical examination findings were significant for marked weakness of the shoulder and hip girdles. His calves were not hypertrophied. Family history was negative for neuromuscular disorders. The CPK levels were elevated on two occasions: the values were 450 and 534 (normal < 200). Electromyogram and muscle biopsy results were consistent with muscular dystrophy.
Question: Does the patient have sporadic DMD/BMD or some other form of muscular dystrophy (e.g., limb-girdle or Emery-Dreifus)? Answer: Dystrophin testing by western blot revealed dystrophin of normal size and abundance (e.g., Fig. 1  A, lane 5) . The presence of normal dystrophin effectively rules out a diagnosis of DMD/BMD, suggesting that the patient has autosomal recessive limb-girdle dystrophy or perhaps the more rare autosomal recessive form of Duchenne-type muscular dystrophy. The patient's DNA was banked for future studies as more disease genes become identified. The parents were counseled that each subsequent pregnancy carried a 25% recurrence risk regardless of fetal sex. In relation to potential therapies, this patient might not be expected to respond to treatments designed specifically for DMD/BMD. Case 5. This is a hypothetical case but could easily be a common situation in the future. Proband is a 3-wk-old male. As part of a newborn screening program, he is found to have an elevated CPK level. Physical examination gives unremarkable findings, and there is no family history of muscle weakness. A repeat CPK test result is also markedly elevated.
Question: Could testing for dystrophin help this family? Answer: Western blotting revealed absence of detectable dystrophin in muscle from this patient, thus establishing a diagnosis of DMD at a time when his parents were planning another pregnancy. PCR analysis detected a deletion in the boy and Southern blotting confirmed this; however, his mother had two normal copies of the dystrophin gene in DNA from her peripheral blood. Because there is a significant probability that she may be germline mosaic, prenatal diagnosis was still offered for all future pregnancies.
